Last reviewed · How we verify
Docetaxel/Paclitaxel
Docetaxel and paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.
Docetaxel and paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis. Used for Metastatic or locally advanced non-small cell lung cancer, Metastatic breast cancer, Gastric adenocarcinoma.
At a glance
| Generic name | Docetaxel/Paclitaxel |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Drug class | Taxane (microtubule-stabilizing chemotherapy) |
| Target | β-tubulin / microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Both drugs belong to the taxane class of microtubule-stabilizing agents. They bind to the β-tubulin subunit of microtubules and prevent their disassembly, which disrupts normal mitotic spindle dynamics and leads to G2/M phase cell cycle arrest. This ultimately triggers apoptosis in rapidly dividing cancer cells. Docetaxel and paclitaxel have similar mechanisms but differ in pharmacokinetics and clinical applications.
Approved indications
- Metastatic or locally advanced non-small cell lung cancer
- Metastatic breast cancer
- Gastric adenocarcinoma
- Head and neck cancer
Common side effects
- Neutropenia
- Peripheral neuropathy
- Alopecia
- Nausea and vomiting
- Fatigue
- Mucositis
- Diarrhea
- Hypersensitivity reactions
Key clinical trials
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (PHASE3)
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (PHASE3)
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors (PHASE1)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |